NCT01583543View on ClinicalTrials.gov

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

November 30, 2014

Conditions
Ewing's Sarcoma
Interventions
DRUG

Olaparib

400mg PO BID Continuous

Trial Locations (3)

02115

Massachusetts General Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01583543 - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | Biotech Hunter | Biotech Hunter